Longeveron (NASDAQ: LGVN) has announced the appointment of Marie Washburn as senior vice president and chief financial officer (CFO), effective July 13, 2026.
Ms. Washburn has served as Longeveron’s vice president and corporate controller since November 2025. She succeeds Lisa Locklear, who, as previously announced, is stepping down.
In a statement, Steven H. Willard, CEO of Longeveron, commented, “Marie has had a tremendously positive impact on the company since joining last year and I am delighted to welcome her as CFO, particularly at this exciting time in Longeveron’s history developing stem cell therapies for vulnerable populations. With our Phase 2b clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome anticipated to produce top-line trial results in third quarter of this year, Longeveron is poised for a significant transformation of our business and development programs.”
